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Robust assessment of genetic effects on quantitative traits or complex-disease risk requires synthesis of evidence from multiple studies.
Frequently, studies have genotyped partially overlapping sets of SNPs within a gene or region of interest, hampering attempts to com-
bine all the available data. By using the example of C-reactive protein (CRP) as a quantitative trait, we show how linkage disequilibrium
in and around its gene facilitates use of Bayesian hierarchical models to integrate informative data from all available genetic association
studies of this trait, irrespective of the SNP typed. A variable selection scheme, followed by contextualization of SNPs exhibiting inde-
pendent associations within the haplotype structure of the gene, enhanced our ability to infer likely causal variants in this region with
population-scale data. This strategy, based on data from a literature based systematic review and substantial new genotyping, facilitated
the most comprehensive evaluation to date of the role of variants governing CRP levels, providing important information on the
minimal subset of SNPs necessary for comprehensive evaluation of the likely causal relevance of elevated CRP levels for coronary-
heart-disease risk by Mendelian randomization. The same method could be applied to evidence synthesis of other quantitative traits,
whenever the typed SNPs vary among studies, and to assist ﬁne mapping of causal variants.Introduction
Genetic effects underlying complex traits and disorders are
small, and their detection requires comprehensive typing
of single nucleotide polymorphisms (SNPs) in large sam-
ples.1,2 Many previous genetic association studies have
been underpowered,3,4 and even very large biobanks5
may not individually provide conclusive results for certain
outcomes. Quantitative synthesis of evidence from avail-
able studies remains vital,6–8 even in the era of genome-
wide analyses.9–11 However, a major obstacle is that studies
of the same gene, region, or even the genome as a whole
may type a different repertoire of SNPs, thereby yielding
partially overlapping genotypic data. Moreover, often
only single SNP summary data, for instance genotype
means at each SNP, is reported.
The meta-analysis of results from each marker in isola-
tion would exclude those studies that did not type the
marker in question, with a potential loss of power; more-
over, multiple single-SNP analyses are difﬁcult to interpret.
Instead, it would be useful to be able to combine data with
information from all sites, adjusting any association at
each site for the possible correlation with the remaining
variants. One could then disentangle effects at causal sitesThfrom those at sites that are in LD with a causal variant(s)
and also borrow information across studies. With focus
on a quantitative trait, we develop a Bayesian hierarchical
linear regression that models linear transformations of the
study-speciﬁc genotype-group-speciﬁc phenotypic means
and that uses pairwise LD measurements between markers
to make posterior inference on adjusted effects. Informa-
tion on pairwise marker LD is often provided by the indi-
vidual studies as part of the results reported. Alternatively,
for markers that are not considered jointly in any of the
study at hand, it can often be obtained from public data-
bases. This information is then used to specify informative
priors in our Bayesian framework. Speciﬁcally, the be-
tween-marker correlations are modeled by introduction
of spatially correlated random effects having a conditional
autoregressive distribution (CAR).12,13 The between-study
variability is then accommodated with a random intercept
term across studies.
Our approach is motivated by the meta-analysis of stud-
ies assessing the effect of variants in the C-reactive protein
(CRP [MIM 123260]) gene region on plasma CRP levels.
CRP is a circulating monomorphic hepatic acute-phase
protein that indexes and may mediate aspects of the in-
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Figure 1. Location of the Eight CRP
SNPs Typed Directly in the 26 Data Sets
Included in This Study
The upper track shows chromosomal lo-
cation; the middle track shows SNP lo-
cation and Log(P) for the per-allele
random-effect meta-analysis (from left
to right, the SNPs are ordered as follows:
rs3093077, rs1205, rs1130864, rs1800947,
rs1417938, rs3091244, rs2794521, and
rs3093059); and the lower track shows the
intron/exon structure of the CRP gene.blood concentrations of CRP show similar within-individ-
ual variability to serum cholesterol, and like cholesterol,
CRP has been shown to be associated with future coronary
heart disease (CHD) risk in observational studies.15 How-
ever, the etiological relevance of this potentially important
and highly studied link with CHD is uncertain because
CRP may simply be a marker for established risk factors
or for subclinical atheroma.16,17 Common SNPs that are
in the gene encoding CRP and that inﬂuence its level
may help provide insight on the link because, unlike
CRP itself, genotype is ﬁxed and unaffected by subclinical
disease and the naturally randomized allocation of alleles
at conception balances the distribution of potential con-
founding factors among genotypic classes. Genetic associ-
ations are therefore less prone to biases that limit causal
inference from observational studies, and genetic studies
possess properties of a randomized intervention trial.16–18
Therefore, identiﬁcation of CRP-gene variants (HGNC:
2637; 1q21-q23) that inﬂuence its concentration is funda-
mental to evaluating the causal relevance of CRP with the
principle of Mendelian randomization.19
In the absence of hepatic stores of CRP, and given its
constant rate of clearance, gene transcription provides
the major point of regulation.14 Transcription may be
modiﬁed by regulatory SNPs because concentrations of
CRP show strong concordance among monozygotic twins
and family studies suggest substantial heritability.20 In
populations of European descent, there are 11 common
SNPs with minor allele frequency >5% within 6 kb of
the CRP gene, but extensive linkage disequilibrium (LD)
means that four major haplotypes account for 94% of
chromosomes (see Web Resources).21,22 Individual reports
evaluating associations of CRP SNPs with CRP concentra-
tion have either typed single SNPs or a subset of SNPs
(sometimes tag SNPs) in this region (see Table S1 available
online). However, the SNPs have varied across studies,
thereby limiting the ability to pool all available data. We
therefore developed a new integrative approach to evi-
dence synthesis of genetic association studies that allows
for this complexity.
Methods for combining data from genome-wide scans
with nonoverlapping sets of SNPs with individual-level
genotyping data have been recently proposed by March-
ini et al.23 Here, because individual-level data are not
available for most of the studies on CRP, we develop860 The American Journal of Human Genetics 82, 859–872, April 20a method that allows the synthesis of studies providing
only summary data. Also, we are mainly concerned with
the synthesis of SNP data in regions of interest for ﬁne
mapping, where the number of markers typed is small
and interest is on disentangling independent effects
using a variable selection scheme, for which the Marchini
approach is not suitable.
Material and Methods
We ﬁrst conducted a literature-based systematic review of all rele-
vant studies (irrespective of the SNP typed). A total of 23 published
data sets identiﬁed by systematic review evaluated associations
of eight SNPs (rs3093059; rs2794521; rs3091244; rs1417938;
rs1800947; rs1130864; rs1205; and rs3093077) in the CRP gene
with CRP concentration (Figure 1). With data from SeattleSNPs,
a combination of three SNPs (rs1130864; rs1205; and rs3093077)
was identiﬁed as haplotype tag SNPs with the haplotype r2method
in European subjects. These tag SNPs were typed in three addi-
tional population-based studies, thereby giving an aggregate of
26 studies including 32,802 subjects. No SNP was typed in every
study, but there was partial overlap of SNP typing across several
studies (see Appendix A and Table S1).
Bayesian Hierarchical Model
We indicate with Yi
s the continuous trait of interest for subject
i˛ 1,.,nsgf and study s˛ 1,.,Sgf . If all studies have genotyped in-
dividuals at allmmarker locations, and these data are available for
all individuals (individual patient data [IPD]), a sensible approach
to pool information across studies would be the random-effect
model
Ys  NCsbþ 1nsms,s2Ins (1)
where Cs is the ns 3 (m þ 1) design matrix coding for the chosen
genetic model (e.g., for an additive models, 0, 1, and 2 for homo-
zygous wild-type, heterozygous, or homozygous mutant geno-
types, respectively) and the intercept term, ms ~N(0, s
2
s) is
a study-speciﬁc random intercept term, 1ns is the n
s 3 1 vector
of ones, Ins is the n
s 3 ns identity matrix, and b ¼ ðb0,b1,.,bmÞ0
is the (m þ 1) 3 1 vector of regression coefﬁcients of interest mea-
suring the effect of genotype group on Y. One could then assess the
relative importance of each marker by using a variable selection
scheme; we use a reversible jump algorithm on the space of possi-
ble models as part of the MCMC scheme as described later in the
text.24,25
However, studies will rarely consider all m markers together;
rather, ms % m will have been typed in study s corresponding to08
a subset Ls of columns of the complete design matrix C
s, Xs say of
size ns 3 (ms þ 1). Also, complete individual patient data for all
studies are rarely available. Instead, we have the summary statis-
tics reported in each study as in the case of the CRP studies. Typi-
cally, data will consist of means, variances, and numbers of indi-
viduals for each genotype groups and each marker. These are
denoted by ysgj, vgj
s , and ngj
s , respectively, for genotype group
g ¼ 1,.,Gj of marker j ˛ {Ls} in study s. The notation allows for
marker-speciﬁc numbers of genotype groups and thus the possibil-
ity of having a mixture of biallelic and triallelic markers, as in the
application to the CRP data, or different genetic models.
Our approach uses Equation (1) as the building block but
models the linear transformations Ts ¼ Xs0Ys as multivariate
normally distributed across studies
Ts  MVNms

Xs
0
CsbþXs01nsms,s2Xs
0
Xs

(2)
where Xs
0
indicates the transpose of Xs. All entries of the vector Ts
can be obtained from the available data summaries. For instance,
the ﬁrst element corresponding to the intercept term is the overall
sum of the y values, and any other entry can be obtained similarly
from the genotype-group-speciﬁc phenotype means and counts
ysgj, n
s
gi:
However, the new design matrixWs ¼Xs0Cs is only partially ob-
served. In particular, only the dot products involving the columns
of Xs with themselves or the intercept term can be derived from
the observed genotype-group counts. The remaining entries are re-
placed by their expected values under Hardy-Weinberg equilib-
rium (HWE) and the known pairwise LD patterns. Speciﬁcally, in-
dicating with whl, h s l, a generic such entry, we ﬁrst obtain an
estimate of the joint bivariate genotype distribution from the
known marginal allele frequencies and the pairwise measure of
LD.26 For example, if both markers are biallelic, this involves esti-
mation of the 3 3 3 matrix of the genotype distribution, and this
estimation is then multiplied by the study size to give expected
counts. Finally, we obtained whl by summing the appropriate en-
tries of the resulting matrix of expected counts multiplied by the
values used to code the genotype groups in the design matrices.
Notice that the vector of coefﬁcients b retains the same interpreta-
tion and scale of the original model in Equation (1) (in the exam-
ple below, additive effect of variants on log CRP plasma levels) be-
cause it is derived from a linear transformation of the variables
therein.
As well as in the derivation of the new design matrixWs, prior
information of between-marker LD patterns is also incorporated
in the speciﬁcation of the (partially unobserved) variance-covari-
ance matrix in Equation (2). Speciﬁcally, we partition s2Xs
0
Xs
into a spatially structured component and a residual, unstruc-
tured, component. We obtained the former by introducing
marker-speciﬁc random effects having a zero-mean conditional
autoregressive distribution
U  CAR

0,s2uðI gRÞ1M

(3)
whereU is a vector of sizem, the number of unique markers across
studies, R is a matrix of weights reﬂecting spatial associations be-
tween the elements ofTs, andM is a diagonalmatrix.12,27 Thus the
covariance matrix in Equation (2) becomes s2u(I  gR)1M þ
s23diag(X
0X) where we set gh 1 and (I  gR)1Mh (X0X  diag
(X0X)), where with X0X we indicate the weighted average of the
study-speciﬁc cross-products Xs
0
Xs with weights given by the
number of subjects in each study. The latter equivalence then
reﬂects our prior information on pairwise LD, as the off-diagonalTheelements of the matrixXs
0
Xs
0
are replaced by their expected values
given the LD patterns.
Conditional on the study and marker-speciﬁc random effects ms
and Uj, the elements of T
s are independent and we can rewrite
Equation (2) as
Tsj jms,Uj  N
 
Wj,,bþ
Xns
i¼1
xsi,jms þ Uj,s2e diag

Xs
0
Xs

j,j
!
(4)
j˛fLsg:
We further assume that the marker and study-speciﬁc pooled
variances
vs:j ¼
P
g

ngj  1

vsgjP
g

ngj  1

have a scaled chi-square distribution
vs:j ¼
s2eP
g ngjs Gjc
P
g
ngjsGj :
Albeit an approximation, this assumption is likely to hold when
the individual SNP associations are modest, as it is reasonable to
expect in this setting. Also, by modeling the observed variances,
we are able to impute any missing values from their full condi-
tional distribution as part of the MCMC scheme.
The hierarchical speciﬁcation is completed by assuming a distri-
bution for the between-studies random effects ms. In order to
accommodate outliers and heavy tails, we assume the mixture
of normals
ms  pNða1,s2mÞ þ ð1 pÞNða2,s2mÞ (5)
with a2 ¼ pa1=ð1 pÞ:28
To select important marker-phenotype associations, we use a re-
versible jump algorithm on the space of models in the MCMC
scheme.24,25 In brief, denoting with k the number of SNP currently
included in a model, we made a proposal to change the current
model by adding amarker, deleting amarker, or swapping amarker
currently in the model with one from the remaining SNPs. The
new model is accepted with probability proportional to its likeli-
hood. Conditional on the accepted model, new values for the ap-
propriate subset of parameters in b are then sampled from their full
conditional distribution. By monitoring the different models
visited, we readily obtained posterior model probabilities. The
algorithm is not guaranteed to visit all possible models, but in
many cases, if the number of available predictors is not large as
here, an acceptable qualitative assessment of the support received
from the data by the different models is possible. Finally,
prior distributions for all remaining unknown parameters are as
follows
bj  Nð0,s2bÞ, j ¼ 1,.,m
a1  Nð0,1e 6Þ
p  Betað1,1Þ
s2m  Gammað0:001,0:001Þ
s2b  Gammað0:001,0:001Þ
s2U  Gammað0:5,0:0005Þ
s2y  Gammað0:001,0:001Þ
where the prior for the precision of the spatial effects is that sug-
gested by Kensall and Wakeﬁeld.29 The reversible jump algorithm
requires speciﬁcation of a prior on model size. Typical choices in-
clude a uniform prior on themodel space or a Poisson or geometricAmerican Journal of Human Genetics 82, 859–872, April 2008 861
distribution on the number of regression terms k included in each
model.25,30,31 The simulation study in the next section includes
a sensitivity analysis of this choice. A graphical representation of
the hierarchical model (4) is given in Figure 2.
Single-Marker Random-Effect Meta-Analysis
Results from themultilocusmodel are compared to those obtained
from a more traditional single-locus random-effects meta-analysis
in both simulation studies and with real data from the CRP-gene
region. For the latter, a per-allele effect (95% CI) of individual
SNPs on CRP concentration was derived from each individual
study. The individual-study linear trend (additive effect) per cate-
gory increase in genotype with mean data was calculated by
simple linear regression, with genotypes coded as 0, 1, and 2 for
homozygous common allele, heterozygous, and homozygous rare-
allele, respectively, with the least-square linear-trend-coefﬁcient
formula, which only depends on the mean values and its standard
deviations. A sensitivity analysis restricted to studies with more
than 500 subjects, healthy at time of blood sampling, or to studies
that reported all the required standard deviations was also con-
ducted (Table S2). Subsequently, the study-speciﬁc linear trend
and its standard error were pooled with random-effect models.
Subsidiary analyses included pairwise comparisons within each
polymorphism. The DerSimonian and Laird Q test, and the I2
test,32 were used for evaluating the degree of heterogeneity
between studies.
Results
Simulation Studies
We considered various scenarios differing in the number of
studies and, for the multilocus approach, in the priors on
the model space. Data were obtained as follows: We ﬁrst
simulated a pool of 4000 haplotypes at seven biallelic
markers. Pairwise LD measures (r) between the seven
Figure 2. Graphical Representation of Equation (4)
Solid and dotted lines represent stochastic and deterministic
dependencies, respectively.862 The American Journal of Human Genetics 82, 859–872, April 20SNPs are shown in Figure 3, with high LD only between
the last three markers. SNP 6 is assumed to be the single
causal site in the region and is retained in all subsequent
analyses. Given the high LD between SNP 5, 6, and 7, we
expect the results from the univariate analyses to be less
conclusive than those from the multiple marker approach
that adjusts for the between-marker correlations. The study
size ns was drawn from a normal distribution with mean
600 and variance 100, rounded to the nearest integer.
Then, for subject i˛ 1,.,nsgf and study s, a continuous
phenotype ysi is simulated as
ysi ¼ b0 þ b6gi6 þ ms þ 3i (6)
where gi6 denotes the genotype of subject i at marker site 6
(0, 1, or 2 for homozygous wild-type, heterozygous, or ho-
mozygous mutant, respectively), (b0, b6) ¼ (1, 2), ms ~ N(0,
1), and 3 ~N(0, 1). To reﬂect the fact that not all markers are
typed in every study, we select at randommsmarkers out of
the possible seven for each study. Thus, in most cases the
univariate analyses are based on fewer than the maximum
total of S studies. For each simulated data set, we also esti-
mated the unadjusted univariate additive effects and their
standard errors at each SNP site; the additive effects are
then combined in the univariate random-effect analy-
ses.33,34 Tables 1 and 2 present the results from the multi-
ple-marker meta-analyses. The number of studies consid-
ered was 10, 20, or 40. In each case, the tables report the
results obtained with Poisson priors on the model size in
the reversible jump algorithm with different means (1 or
2 for priors a and b, respectively) or a uniform prior on
the model space (prior c). Notice that the Poisson priors
give more weight to the null model and may in general
be a more reasonable choice in this setting. For example,
Figure 3. Pairwise LD Measures between Markers Used in the
Simulation Study
Pairwise LD Measures are r values.08
prior a is Poisson(1) and assigns a probability of ~0.26 of
having more that one associated site (~0.59 for b). The
values shown are averages over 100 replicates. For each sce-
nario, we report the marginal posterior probability of se-
lecting each SNP and the mean and 95% credible intervals
of the posterior distributions of each additive effect, condi-
tional on the SNP being selected.35,36 Note that posterior
distributions can be reliably estimated only for markers
with relatively high posterior probability of inclusion
(e.g., >0.5), and results in the table should be interpreted
Table 1. Bayesian Multilocus Meta-Analysis
Parameter b1 b2 b3 b4 b5 b6 b7 s
2
y sm
2
Number of Studies Prior True 0 0 0 0 0 2 0 1 1
Post proba 0.01
(0.01)
0.01
(0.004)
0.01
(0.004)
0.005
(0.002)
0.01
(0.01)
1.00
(0.00)
0.03
(0.02)
a Meana 0.01
(0.05)
0.004
(0.04)
0.03
(0.03)
0.01
(0.03)
0.01
(0.07)
2.00
(0.04)
0.16
(0.14)
1.19
(0.01)
1.25
(0.61)
BCI length 0.19 0.20 0.15 0.14 0.35 0.19 0.76
Post prob 0.02
(0.01)
0.01
(0.004)
0.01
(0.01)
0.01
(0.004)
0.02
(0.01)
1.00
(0.001)
0.07
(0.08)
10 b Mean 0.03
(0.04)
0.01
(0.03)
0.03
(0.03)
0.02
(0.03)
0.01
(0.08)
2.00
(0.05)
0.15
(0.16)
1.08
(0.02)
1.13
(0.34)
BCI length 0.24 0.22 0.16 0.15 0.36 0.23 0.76
Post prob 0.05
(0.02)
0.04
(0.02)
0.04
(0.02)
0.03
(0.01)
0.07
(0.03)
1.00
(0.001)
0.15
(0.05)
c Mean 0.03
(0.04)
0.01
(0.04)
0.02
(0.03)
0.01
(0.03)
0.01
(0.07)
1.99
(0.04)
0.13
(0.12)
1.12
(0.01)
1.42
(0.46)
BCI length 0.24 0.21 0.17 0.15 0.35 0.33 0.76
Post prob 0.01
(0.01)
0.01
(0.002)
0.01
(0.003)
0.004
(0.002)
0.01
(0.003)
1.00
(0.00)
0.03
(0.08)
a Mean 0.04
(0.03)
0.02
(0.03)
0.03
(0.02)
0.01
(0.02)
0.01
(0.05)
1.99
(0.04)
0.09
(0.10)
1.11
(0.01)
1.10
(0.26)
BCI length 0.16 0.14 0.11 0.10 0.23 0.12 0.56
Post prob 0.02
(0.02)
0.01
(0.01)
0.01
(0.01)
0.01
(0.003)
0.02
(0.01)
1.00
(0.001)
0.05
(0.04)
20 b Mean 0.04
(0.03)
0.02
(0.03)
0.02
(0.03)
0.01
(0.02)
0.02
(0.05)
1.99
(0.03)
0.13
(0.112)
1.06
(0.01)
1.08
(0.17)
BCI length 0.16 0.15 0.12 0.10 0.24 0.17 0.57
Post prob 0.06
(0.05)
0.03
(0.01)
0.03
(0.01)
0.02
(0.01)
0.06
(0.05)
1.00
(0.002)
0.13
(0.08)
c Mean 0.05
(0.03)
0.02
(0.02)
0.02
(0.02)
0.01
(0.02)
0.01
(0.06)
1.99
(0.03)
0.10
(0.108)
1.09
(0.01)
0.99
(0.16)
BCI length 0.18 0.15 0.12 0.11 0.26 0.23 0.59
a Results are averages (std) over 100 replicateddata sets.Meanposterior estimates andcredible intervals are conditional on the SNPbeing included in amodel.Table 2. Bayesian Multilocus Meta-Analysis
Parameter b1 b2 b3 b4 b5 b6 b7 s
2
y sm
2
Number of Studies Prior True 0 0 0 0 0 2 0 1 1
Post prob 0.01
(0.15)
0.01
(0.003)
0.004
(0.002)
0.003
(0.001)
0.01
(0.004)
1 (0) 0.025
(0.28)
a Mean 0.05
(0.02)
0.03
(0.02)
0.02
(0.02)
0.01
(0.01)
0.02
(0.04)
1.99
(0.02)
0.10
(0.08)
1.04
(0.01)
1.09
(0.14)
BCI length 0.12 0.10 0.08 0.07 0.17 0.10 0.46
Post prob 0.03
(0.03)
0.01
(0.01)
0.01
(0.00)
0.01
(0.002)
0.02
(0.01)
1 (0) 0.04
(0.03)
40 b Mean 0.05
(0.02)
0.02
(0.02)
0.02
(0.02)
0.01
(0.02)
0.03
(0.03)
1.99
(0.02)
0.12
(0.07)
1.03
(0.01)
0.97
(0.13)
BCI length 0.12 0.11 0.08 0.07 0.19 0.12 0.46
Post prob 0.07
(0.06)
0.03
(0.01)
0.02
(0.01)
0.01
(0.01)
0.04
(0.02)
1 (0) 0.11
(0.06)
c Mean 0.05
(0.02)
0.03
(0.02)
0.02
(0.02)
0.01
(0.01)
0.01
(0.04)
1.99
(0.02)
0.10
(0.10)
1.03
(0.01)
1.01
(0.11)
BCI length 0.12 0.11 0.10 0.077 0.19 0.18 0.48
Results are averages (std) over 100 replicated data sets. Mean posterior estimates and credible intervals are conditional on the SNP being included in amodel.
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Table 3. Single-Locus Random-Effects Meta-Analysis
SNP ID 1 2 3 4 5 6 7
Number of Studies True 0 0 0 0 0 2 0
Mean (std) 0.033
(0.028)
0.023
(0.024)
0.069
(0.026)
0.312
(0.026)
1.158
(0.039)
1.990
(0.040)
1.945
(0.036)
10 Mean BCI length 0.385 0.379 0.367 0.365 0.414 0.434 0.482
Mean (std) 0.03
(0.018)
0.019
(0.018)
0.072
(0.017)
0.314
(0.017)
1.169
(0.025)
1.999
(0.026)
1.942
(0.03)
20 Mean BCI length 0.258 0.253 0.245 0.244 0.269 0.286 0.327
Mean (std) 0.032
(0.014)
0.021
(0.012)
0.067
(0.013)
0.311
(0.015)
1.165
(0.02)
1.998
(0.017)
1.94
(0.021)
40 Mean BCI length 0.183 0.179 0.175 0.175 0.194 0.203 0.23
Results are averages over 100 replicated data sets.with this inmind. Themarginal probability of selecting the
causal site is 1 independently of the prior used and even
when considering as few as ten studies, with almost no var-
iability across replicates. Notably, all other markers have
posterior inclusion probabilities close to zero and would
therefore not be selected if we were to use the traditional
threshold of 0.5. All conditional mean additive effects are
very close to the true values with a minor bias only for the
effect at SNP 7, which is the SNP in highest LD with the
causal site. The choice of prior distribution on model space
does not have a large effect on the results, with possibly nar-
rower credible intervals and slightly larger posterior proba-
bility of including SNP 7 under prior c compared to priors
a and b. This is to be expected because the Poisson priors
favor models with few terms, whereas the uniform prior
gives equal weight to all models. The tables also report the
results for the variance terms s2m and s
2
y, which have
posterior estimates close to the true values in both cases. In-
creasing thenumber of studies has little or no effect onboth
marginal posterior probabilities and posterior estimate bias
but does lead to narrower credible intervals as expected.The univariate analyses on the other hand fail to unam-
biguously identify the causal site at position 6 (Table 3). On
the basis of results reported therein, although SNP 6 shows
the highest association with the phenotype, SNP 7 could
still be considered causal if no prior information is avail-
able to discriminate between the two. Even markers 4
and 5 would be selected on the basis of posterior credible
intervals; paradoxically, increasing the number of studies
only exacerbates the problem because credible intervals
become narrower.
The previous simulation study assumed the same LD
pattern across studies because study-speciﬁc genotype
data are simulated from a common haplotype pool. To
mimic a more realistic scenario, we further considered
study-speciﬁc LD patterns by simulating genotype counts
from study-speciﬁc haplotype pools characterized by
slightly different LD structures. The multilocus analysis
then uses the average LD table shown in Figure D1 (in
which we also report the standard deviations of the pair-
wise r2 values across studies in brackets). Results are re-
ported in Table 4 for replicates with 20 studies. ThemethodTable 4. Bayesian Multilocus Meta-Analysis when the LD Structure Is Allowed to Vary across Studies
Number
of studies
Parameter b1 b2 b3 b4 b5 b6 b7 s
2
y sm
2
Prior True 0 0 0 0 0 2 0 1 1
Post prob 0.01
(0.01)
0.01
(0.01)
0.03
(0.02)
0.03
(0.06)
0.01
(0.01)
1.00
(0.00)
0.03
(0.03)
a Mean 0.02
(0.04)
0.02
(0.03)
0.07
(0.01)
0.04
(0.04)
0.01
(0.06)
1.97
(0.01)
0.13
(0.11)
1.06
(0.02)
1.07
(0.23)
BCI length 0.16 0.15 0.10 0.10 0.23 0.14 0.58
Post prob 0.01
(0.01)
0.01
(0.01)
0.02
(0.01)
0.01
(0.01)
0.02
(0.01)
1.00
(0.00)
0.08
(0.05)
20 b Mean 0.01
(0.04)
0.01
(0.04)
0.06
(0.02)
0.02
(0.04)
0.01
(0.07)
1.98
(0.04)
0.14
(0.28)
1.08
(0.02)
1.03
(0.13)
BCI length 0.2 0.12 0.15 0.15 0.32 0.29 0.67
Post prob 0.03
(0.01)
0.03
(0.01)
0.11
(0.13)
0.10
(0.08)
0.04
(0.05)
1.00
(0.00)
0.12
(0.04)
c Mean 0.02
(0.03)
0.02
(0.02)
0.05
(0.03)
0.04
(0.04)
0.01
(0.04)
1.99
(0.03)
0.15
(0.05)
1.04
(0.01)
1.07
(0.12)
BCI length 0.17 0.15 0.12 0.10 0.22 0.24 0.58
Results are averages (std) over 100 replicated data sets. Mean posterior estimates and credible intervals are conditional on the SNP being included in
a model. See Figure D1.
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Figure 4. Summary Effect from Tradi-
tional Meta-Analysis and Bayesian Mul-
tiple-SNP Hierarchical Linear Model of
the Eight SNPs in the CRP Gene
Values shown are additive genetic effects
on (log) CRP levels with 95% confidence
intervals or credible intervals for tradi-
tional and Bayesian analyses, respectively.
For the Bayesian analysis, results are
shown only for those markers that appear
to be strongly associated after variable
selection (see Figure 5). N/A refers to
SNPs excluded from the model. The asterisk
indicates the dominant model. Negative
values indicate the variant allele is associ-
ated with a lower CRP concentration.appears to be fairly robust to minor deviations in LD pat-
terns across studies (similar to those observed for the real
data in the next section); large differences in LD structures
across studies would necessarily invalidate the meta-
analytical approach because there would be little informa-
tion to borrow for variable selection.
Finally, we considered reducing the effect at the causal
site to 1.5 or placing it at marker position 2, which is in
linkage equilibrium with the other sites: In both cases,
the causal site is selected with high posterior probability
(>0.8, results not shown).
The WinBUGS code used to ﬁt the model is given in
Appendix C.
A Meta-Analysis of CRP Studies
The traditional single-locus meta-analyses require that the
available data be partitioned into groups of studies in
which the same SNP was typed directly. In these analyses,
seven SNPs were associated with a codominant effect on
CRP concentration (Figure 4) with the per-allele effect
in the range of 0.19–0.58 mg/L (absolute p values:
rs1800947 ¼ 4.35 3 109; rs1205 ¼ 7.76 3 1026;
rs1417938 ¼ 1.77 3 102; rs1130864 ¼ 2.73 3 1011;
rs3091244 ¼ 4.50 3 1015; rs3093077 ¼ 5.03 3 1011;
and rs3093059 ¼ 2.27 3 108), corresponding to ~0.3–
0.8 SD of the population distribution of CRP 37. The
main effect estimates were robust to analyses limited to
studies of >500 subjects (Table S2), providing strong evi-
dence for an association at this locus. However, because
pooled analyses of this type are limited to individual
SNPs, it is unclear which of these SNPs have independent
effects and which are associated because of correlation
with other observed or unobserved SNPs, including the
true causal variant(s). This can be overcome by incorporat-
ing available information on pairwise LD in the region (Ta-
ble S3) within a Bayesian multilocus model as describedTheabove. Bayesian model selection can then facilitate identi-
ﬁcation of variants showing the strongest independent
association with CRP concentration (Figure 5 and Table
5). The approach yields posterior model probabilities
Figure 5. Results from the Multiple-SNP Meta-Analysis using
the Bayesian Hierarchical Linear Model
The shaded bars show the posterior probability that each SNP is
included in amodel, calculated from the posterior sample of models.
The x axis indicates the additive effects of each SNP on log CRP
plasma levels, conditional on that SNP being included in the model,
and the y axis indicates the corresponding posterior density. The
curves can thus be interpreted as smoothed histograms representing
the probability that the SNP effects take the values on the x axis.
Also shown are the densities, medians (:), and 95% credible inter-
vals (- - -) for the additive effects of each SNP on log CRP levels.American Journal of Human Genetics 82, 859–872, April 2008 865
Table 5. Application to the Meta-Analysis of CRP Studies
Prob
SNP included
rs3093059 rs2794521 rs3091244 rs1417938 rs1800947 rs1130864 rs1205 rs3093077
0.22    
0.12   
0.10    
0.07   
0.06     
Models with more than 2% posterior probability are shown. Results assume a Poisson(2) prior on model size in the reversible jump algorithm.conditional on the observed data from which marginal
probabilities of association for each SNP can be readily
obtained. Of the markers considered, SNPs rs1130864,
rs1205, and rs3093077, all in the 3 UTR, retain the stron-
gest independent association with CRP concentration.
An additional synonymous SNP in exon 2 (rs1800947) ap-
pears to be important, although its posterior probability of
association is sensitive to the prior on themodel space, and
becomes unimportant if a more restrictive prior on the
number of associated markers in the region is used (results
not shown). These four SNPs yield the model with the
highest posterior probability (Figures 4 and 5 and Table
5). Again, the models were not materially altered when
analyses were limited to studies of >500 subjects (results
not shown).
Notably, SNPs rs1130864, rs1205, and rs3093077 formed
the trio of tag SNPs. Because each tag SNPmarks a different
haplotype, the Bayesian model implies the presence of at
least three functional SNPs regulating CRP level (Figure 6).
Using HapMap, we found that there were 11 SNPs in strong
LD with rs1205, (ﬁve with pairwise r2 ¼ 1) within an asso-
ciated interval of ~100 kb. There were 11 SNPs in strong LD
with rs3093077 (nine with pairwise r2 ¼ 1), within a larger
associated interval of ~300 kb. A total of 22 SNPs lay in an
associated interval of 100 kb encompassing rs1130864
(nine with pairwise r2 ¼ 1) (Figure 7). Because tightly
linked SNPs were identiﬁed in the associated intervals,866 The American Journal of Human Genetics 82, 859–872, April 2a careful assessment of potential functionality for each of
these SNPs is now required.
As mentioned in the previous section, in order to accom-
modate outliers and heavy tails, we assumed the distribu-
tion of the between-studies random effects ms to be a mix-
ture of normals. In particular, inspection of the residuals
from a model ﬁtted without the between-studies random
effect appears to suggest the use of a two-component
mixture, see Figure 8. The graph plots a sample of the
quantities
rsj ¼ Tsj Wj,:ðt Þb
ðtÞ  U ðtÞj (7)
for current values of the spatial random effects U and
model at iteration t.28 The posterior distribution of a1
and a2 had means of 0.014 and 3.356, respectively (Fig-
ure 8), whereas p had posterior median estimate of
0.879. By monitoring the mixture component assign-
ments of each study, we found that outlying studies were
mostly assigned to the second component as expected
(results not shown).
Discussion
With only small genetic effects expected to contribute to
most complex diseases, the meta-analysis of studies that
consider variants in the same genetic region is a promisingFigure 6. A Reduced Median Network
Constructed with HapMap CEPH Data for
a 20 kb Region Containing the CRP Gene
Yellow circles indicate haplotypes. The size
of each circle is proportional to the fre-
quency of that haplotype in the HapMap
CEPH population. Non-HapMap SNPs (indi-
cated in italics) were placed on the net-
work with information from other CEPH
populations.008
Figure 7. Genomic Context for CRP Gene
(A) Ideogram depicting the chromosome and region in which the CRP gene lies (red line).
(B) Gene diagram with introns and exons depicted as horizontal and vertical blue lines, respectively.
(C) Pairwise r2 LD values between independently associating SNPs from Bayesian analysis (identified in top left of window, position
indicated by red arrow) and all other HapMap SNPs in the region (release 20, build 35, red ¼ r2 > 0.8, yellow ¼ 0.5 < r2 < 0.8, gray ¼
0.3 < r2 < 0.5, blue ¼ 0.2 < r2 < 0.3, and dark gray ¼ missing data).
strategy to increase our chances of ﬁnding any associa-
tions. Recognizing the importance of this approach, sev-
eral coordinated efforts have been initiated to ensure that
results from the individual studies follow agreed guidelines
and can be combined more easily.7
Most of the meta-analyses conducted so far have consid-
ered each marker in isolation, ignoring the possible corre-
lation between markers due to linkage disequilibrium that
reduces efﬁciency and that compromises the identiﬁcation
of any causal site. In this paper, we have presented a multi-
marker approach that yields estimates of effect at each site
adjusted for the effects of other variants, as in multiple re-
gression. In both the simulation study and the application
to the CRP data, we assumed an additive genetic model.
Other choices are possible andwould only involve changes
in the entries of the matricesW and X0X.
The methods borrow from the spatial data literature and
incorporate the prior knowledge of marker pairwise LD in
a fully Bayesian framework. For example, similar hierarchi-
cal models with spatial random effects are used extensivelyThein the analysis of spatial epidemiological data. A conve-
nient feature of the joint speciﬁcation (Equation [3]) is
that it allows incorporation of the required correlation
structure as prior information in an explicit way.13,37 In ad-
dition, a reversible jump algorithm on the space of possible
model structures enables the selection of the most promis-
ing associations. The proposed approach assumes data on
a continuous phenotype. However, it could be extended
to the case of discrete outcomes, say case-control status,
by introducing a further set of continuous latent variables
related to the discrete outcome as in probit regression. Ex-
tensions to include metaregression are straightforward and
only involve introduction of a further hierarchy for the
vector of coefﬁcients b in Equation (4) with means that
would then depend on study-speciﬁc covariates. Work on
these extensions is currently in progress.
When applied to themeta-analysis of studies in the CRP-
gene region, results provide evidence for three CRP modi-
fying alleles distributed over three of four common haplo-
types in Europeans. These alleles could account for theAmerican Journal of Human Genetics 82, 859–872, April 2008 867
strong association with CRP of each of the three SNPs that
are chosen for their ability to tag others and that mark the
different haplotypes. The associated interval for each inde-
pendently associating SNP extended at least 100 kb from
either side of the open reading frame with a very sharp
boundary of LD for at least two of these. Within each inter-
val were a number of additional candidate causal SNPs in
complete LD with the index SNP from the Bayesian analy-
sis, any of which could, in theory, regulate CRP. Although
the A and T alleles of the triallelic SNP rs3091244 appeared
to exhibit functionality in previous reporter-gene studies
in vitro,21 this SNP was not retained within the Bayesian
model. Experimental studies of this type may be biased to-
ward the study of potential regulatory SNPs in the immedi-
ate vicinity against those located remotely from the gene
of interest because of size constraints on reporter-gene con-
structs. This might explain why results of such reporter
studies are, at times, discordant with the ﬁndings of associ-
ation analyses in populations38 or alternative experimen-
tal approaches to assessing functionality.39 Irrespective of
the true causal sites, the three tag SNPs adequately capture
functional variation at this locus for large-scale gene-
disease association studies. Although the naive expecta-
tion would be of narrower limits of error around the point
estimates of SNP effects with a Bayesian approach that
includes all studies simultaneously, this was not observed.
This is because unlike the traditional meta-analyses, the
Bayesian analyses were corrected for the effect of other
SNPs; that is, uncertainty about which SNPs are directly
associated with the trait was properly incorporated in
the analyses. However, the simultaneous use of all data
strengthens evidence for an association at the gene level;
the null model does not appear at all in the posterior
Figure 8. Posterior Sample of Residuals from the Hierarchical
Model of Material and Methods Fitted without the Between-
Study Random-Effect Term ms868 The American Journal of Human Genetics 82, 859–872, April 2sample of models, reﬂecting virtual certainty of an effect
on CRP at this gene.
Our approach facilitates the integration of data from
studies that have genotyped different SNPs across the
same gene or region utilizing prior information on LD. It
has a number of favorable attributes and potential applica-
tions. By increasing the available data set of information
on any SNP, the efﬁciency of evidence synthesis is en-
hanced and the reliability of any identiﬁed associations is
increased. Further, the variable selection procedure allows
inference on the relative magnitude of any marker-pheno-
type association and identiﬁes those SNPs that show the
strongest association with the phenotype, either because
they are the functional site(s) or because they exhibit the
strongest allelic association with (unobserved) functional
sites. IPD (where available) can also be incorporated readily
into the analysis because the regression parameters mea-
suring the effect of variants retain the same interpretation
when considering aggregate data (i.e., phenotype means
by genotype groups as with CRP studies) or IPD (see Mate-
rial and Methods). Moreover, where a robust evidence
based on genetic association with a quantitative trait al-
ready exists (as it does for many blood measures, e.g.,
HDL cholesterol, triglycerides, and others), the methods
described could be used to add and integrate partially over-
lapping SNP data from new genome-wide analyses,
thereby harnessing existing data for both replication, and
to gain insight into likely causal sites in a gene or region.
The methods we describe, which use the freely available
software WinBUGS, are likely to be of substantial value
both to the emerging networks of investigators engaged
in synthesis of evidence on genetic associations of com-
plex quantitative traits and disorders7 and to those apply-
ing and extending ﬁndings from genome-wide association
studies.
Appendix A
Systematic Review
Two electronic databases (PubMed Medline and EMBASE)
were searched with the text words, which were also
MeSH terms, polymorphism(s), mutation(s), gene(s), ge-
netic, variant(s), and SNP(s) in combination with C-reac-
tive protein and CRP. The literature search was limited to
human and to the English language. Any additional stud-
ies in the references of all identiﬁed publications were
also searched. For inclusion, studies had to have an analyt-
ical design (case control, prospective, or cross sectional)
and examine the association between any polymorphisms
in the CRP gene and low-chronic CRP concentrations in
individuals of European descent. Studies measuring CRP
only during acute phase of an inﬂammatory response (e.g.,
acute ischemia or infection stimuli) were excluded. In areas
where more than one polymorphism had been studied, in-
formation about the LD between them was extracted
where available. If relevant information was not reported008
(mean CRP levels, standard deviations, genotype numbers,
or linkage disequilibrium data), or it was not reported strat-
iﬁed by ethnicity, the authors were contacted in several oc-
casions to obtain the information. A total of four potential
studies (n ¼ 2614) in European subjects were excluded be-
cause of unavailability of data in the appropriate form (Flex
2004, n ¼ 471; Obisesan 2004, n ¼ 63; Zee 2004, n ¼ 260;
Carlson 2005, n ¼ 1820) (see Table S1).
New Data Sets
NPHS II is a prospective study of 3012 healthy white Euro-
pean middle-aged men, of which a total of 2479 with CRP
genetic data and CRP concentrations were included in this
report. Recruitment in the study commenced in 198940
in nine general practices. None of the participants had
a clinical history of unstable angina, myocardial infarction
(including silent infarction), coronary surgery, other car-
diovascular diseases, aspirin or anticoagulant use, or malig-
nant disease (except skin cancer other than melanoma) at
the time of recruitment. The Ely Study is a prospective pop-
ulation-based cohort study of the etiology and pathogene-
sis of type 2 diabetes and related metabolic disorders in
1122 individuals recruited in 1990 in Ely, Cambridge-
shire.41 Complete data on biochemical and anthropomet-
ric variables were available in 839 participants, and a total
of 548 individuals with data on the CRP genotypes and
CRP levels were included in this analysis. The EPIC-Norfolk
study is a population-based cohort study, recruiting partic-
ipants from general practices in Norfolk.42 For the present
report, only control participants from a nested case-control
study in coronary heart disease were included, providing
a total of 2196 participants with both data on CRP genetic
variants and CRP concentrations.
New Genotyping
Polymorphisms in the human CRP gene (HGNC: 2637;
1q21-q23) were identiﬁed by reference to public-domain
databases of human sequence variation. We used this in-
formation to generate a consensus map of polymorphic
sites. By using validated genotype data (minor allele fre-
quency >5%) from subjects of European descent from
the SeattleSNPs database and the humanHapMap database
(see Web Resources), we examined the pattern of linkage
disequilibrium across the CRP gene. We then used the
haplotype LD r2 method to select a set of tagging (t)SNPs
capable of capturingmaximumhaplotype diversity among
subjects of European descent by using the program TagIT
(see Web Resources).
LD
Public domain databases (see Web Resources) and individ-
ual publications were examined for information on the
LD structure in the CRP gene. Both D0 and r2 values were
recorded, but r2 values were utilized in Bayesian modeling.
If more than one r2 value for a given pairwise was reported,
a weighted mean r2 was obtained.ThAppendix B
Recovering the Joint Distribution of Multiallelic Sites
from Allele Frequencies and Marginal Diallelic r2
Values
We consider two loci, the ﬁrst locus having G1 ¼ three
alleles and the second locus having G2 ¼ two alleles. The
joint probability of the haplotypes at these two loci can
be represented in a 3 3 2 table of the form:
wherepijdenotes the jointprobabilityofallele iat locus1and
allele j at locus 2, Pi denotes the probability of allele i at locus
1, and Q1 denotes the probability of allele 1 at locus 2.
The internal cells of this table are not observed. Our prob-
lem is toderive this tableofprobabilitiesonthebasis of infor-
mation from the margins of this table (P1, P2 and Q1) and
pair-wise correlationwithin twomarginal tables of the form:
and
In the ﬁrst of these tables, p011 denotes the joint probability
of allele 1 at locus 1 and allele 1 at locus 2, but now this
probability is conditional upon the allele at locus 1 having
either a 1 or 3 allele. Similarly, p21 denotes the probability
of allele 2 at locus 1 and allele 1 at locus 2 conditional upon
the allele at locus 1 being either a 2 or a 3.
We do not observe the two tables above but only the ap-
propriate deviations from linkage disequilibrium, d013 and
d0023, deﬁned by
d13 ¼ P01 Q
0
1  p
0
11
and
Table B1. Full 3 3 2 Table of Haplotype Probabilities
Allele at
Locus 1
Allele at Locus 2
1 2
1 p11 P1  p11 P1
2 p21 P2  p21 P2
3 Q1  p11  p21 (1  Q1)  (P1  p11) 
(P2  p21)
(1  P1  P2)
Q1 (1  Q1) 1
Table B2. First Marginal 2 3 2 Haplotype Table
Allele at Locus 2
Allele at Locus 1 1 2
1 p011 P01  p011 P01
3 Q01  p011 (1  Q01)  (P01  p011) (1  P01)
Q01 (1  Q01) 1
Table B3. Second Marginal 2 3 2 Haplotype Table
Allele at Locus 2
Allele at Locus 1 1 2
2 p0021 (P002  p0021) P002
3 Q001  p0021 (1  Q001)  (P002  p0021) (1  P002)
Q001 (1  Q001) 1e American Journal of Human Genetics 82, 859–872, April 2008 869
d023 ¼ P002  Q 001  p0021:
We know that the probability of each pair-wise haplo-
type in Table 2 is equal to the corresponding probability
of that pairwise haplotype in Table 1, divided by the prob-
ability that the allele at the ﬁrst locus is either equal to 1 or
3, (1  P2). This means that:
p011 ¼
p11
ð1 P2Þ
and
ðQ 01  p011Þ ¼
ðQ1  p11  p21Þ
ð1 P2Þ :
Therefore,
Q 01 ¼
ðQ1  p11  p21Þ
ð1 P2Þ þ
p11
ð1 P2Þ
¼ ðQ1  p21Þð1 P2Þ ,
and
p11 ¼ p11ð1 P2Þ:
Following a similar argument, we also ﬁnd that
Q 001 ¼
ðQ1  p11Þ
ð1 P1Þ
and
p21 ¼ p21ð1 P1Þ:
By writing p011 and p0021 in terms of d013 and d0023, we ﬁnd
that:
p11 ¼ p011ð1 P2Þ
¼ ðP01 Q 01  d011Þð1 P2Þ
¼
 P1
ð1 P2Þ
ðQ1  p21Þ
ð1 P2Þ  d
0
11

ð1 P2Þ
¼ 1ð1 P2Þ

P1Q1  P1p21  d011ð1 P2Þ2

and
p21 ¼ p021ð1 P1Þ
¼ ðP002 Q 001  d021Þð1 P1Þ
¼
 P2
ð1 P1Þ
ðQ1  p11Þ
ð1 P1Þ  d
00
21

ð1 P1Þ
¼ 1ð1 P1Þ

P2Q1  P2p11  d0021ð1 P1Þ2

:
This means that we have two equations in two un-
knowns, p11 and p21, so that by substituting the second
equation for p21 into the ﬁrst equation for p11, we can
then solve this equation in terms of p11. Substituting the
expression for p12 into that for p11 gives:
p11 ¼ 1ð1 P2Þ

P1Q1  P1p21  d011ð1 P2Þ2

¼ 1ð1 P2Þ

P1Q1  P1ð1 P1Þ

P2Q1  P2p11
 d0021ð1 P1Þ2

 d011ð1 P2Þ2

,
and rearranging in terms of p11 results in the equation:870 The American Journal of Human Genetics 82, 859–872, April 20p11 ¼ P1Q1 þ ð1 P1Þð1 P1  P2Þ

P1ð1 P1Þd0021  ð1 P2Þ2d011

:
We may then write p21 in the form
p21 ¼ P2Q1 þ ð1 P2Þð1 P1  P2Þ

P2ð1 P2Þd011  ð1 P1Þ2d0021

:
We are now able to calculate the probability of every cell
of Table B1 in terms of p11, p12, P1, P2, and Q1.
Note that d011 and d0021 can be obtained from the relevant
r2 values with the formulae:
d011 ¼ ð þ= Þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðr011Þ2P01ð1 P01ÞQ 01ð1 Q 01Þ
q
and
d0021 ¼ ð þ= Þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðr 0021Þ2P002ð1 P002ÞQ 001ð1 Q 001Þ
q
:
Care must be taken when choosing which sign to assign
these d values because they must be consistent with the
margins of the Tables B2 and B3.
Appendix C
WinBUGS Code for the Model Described in Material
and Methods
model {
# likelihood
for(j in 1:Q) {# where Q ¼Ps ðms þ 1Þ
T[j] ~dnorm(theta[j],tauy[j])
tauy[j]) tau.y/XsXs[j] # XsXs[j] in Equation (4)
theta[j]) psi[j]þsumXis[j]*mu[study[j]]þU[marker[j]] #
linear predictor in Equation (4)
}
# pooled variances
for(i in 1:L) {# where L ¼Ps ms
scale[i]) tau.y/2
shape[i]) pooled[i,2]/2
pooled[i,1] ~dgamma(shape[i],scale[i]) # uses the gamma
parameterization
}
#reversible jump part as detailed in Lunn et al.25
psi[1:Q]) jump.lin.pred(W[1:Q,1:m],K,tau.beta)
id) jump.model.id(psi[1:Q])
pred[1:(mþ1)]) jump.lin.pred.pred(psi[1:Q],X.pred[1:
(mþ1),1:m])
for(i in 1:m){
X.pred[i,i]) 1
for(j in 1:(i1)) {X.pred[i,j]) 0}
for(j in (iþ1):m) {X.pred[i,j]) 0}
X.pred[(mþ1),i]) 0
effect[i]) pred[i] -pred[mþ1]
}
# mixture distribution for study effects
for(s in 1:nstudies) {
mu[s] ~dnorm(mumu[s],tau.mu)08
mumu[s]) alpha[comp[s]]
comp[s] ~dcat(phi[ ])
}
phi[2]) 1-phi[1]
alpha[2]) (-phi[1]*alpha[1])/(1-phi[1])
# prior distributions
U[1:m] ~car.proper(thetaU[ ],M[ ],adj[ ],num[ ],m[ ],prec,1)
# thetaU vector of zeros of length m (number of unique
markers)
# M is weighted average of the Xs
0
Xs matrices
# details on vectors adj, num and m are given in the
manual for GeoBUGS
prec ~dgamma(0.5,0.0005)
tau.y ~dgamma(0.001,0.001)
tau.mu ~dgamma(0.001,0.001)
tau.beta ~dgamma(0.0001,0.0001)
phi[1] ~dbeta(1,1)
alpha[1] ~dnorm(0.0,1.0E-6)
K ~dpois(1) # scenario (a)
}
The MCMC chain was run for 1,000,000 iterations with
a burn-in of 500,000 and thinning of 100 iterations, which
took ~30min of CPU time on an Itel Xeon 2.80 GHz with 2
GB of RAM. Convergence was checked by visual inspection
of posterior traces and by running chains with different
initial values.36
Appendix D
Figure D1. Mean Pairwise LD Measures between Markers Used
in the Simulation Study when Allowing LD Patterns to Vary
across Studies
Supplemental Data
Three tables are available at http://www.ajhg.org/.ThAcknowledgments
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Web Resources
The URLs for data presented herein are as follows:
CRP:C-reactiveprotein,pentraxin-related,http://pga.gs.washington.
edu/data/crp/
HapMap homepage, http://www.hapmap.org/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/Omim
TagIT, http://popgen.biol.ucl.ac.uk/software.html
WinBUGS software, http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/
contents.shtml
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